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Objectives: Although	 the	hepatomitogenic	 activity	of	 triiodothyronine	 (T3)	 is	well	
established,	 the	wide	range	of	harmful	effects	exerted	by	this	hormone	precludes	
its use in liver regenerative therapy. Selective agonists of the beta isoform of thy-
roid	hormone	 receptor	 (TRβ)	 do	not	exhibit	T3-induced	cardiotoxicity	 and	 show	a	
good	safety	profile	in	patients	with	NASH.	The	aim	of	this	study	was	to	investigate	
whether two novel TRβ	agonists,	the	prodrug	TG68	and	the	active	compound	IS25	
could	stimulate	hepatocyte	proliferation	without	T3/TRα-dependent side effects.
Methods: Rats	were	treated	with	three	different	doses	 (12.5,	25	and	50	μg/100 g 
body	weight)	 for	 one	week.	 Hepatocyte	 proliferation,	 liver	 injury	 and	 serum	 bio-
chemical	 parameters	 were	 measured	 by	 immunohistochemistry,	 qRT-PCR	 and	
Western blot.
Results: Both drugs increased hepatocyte proliferation as assessed by bromode-
oxyuridine	incorporation	(from	14%	to	28%	vs	5%	of	controls)	and	mitotic	activity.	
Enhanced proliferation occurred in the absence of significant signs of liver injury as 
shown	by	 lack	of	 increased	serum	transaminase	 levels	or	of	apoptosis.	No	cardiac	
or	 renal	 hypertrophy	 typically	 associated	 with	 treatment	 with	 T3	 was	 observed.	
Importantly,	no	proliferation	of	pancreatic	acinar	cells,	such	as	that	seen	after	admin-
istration	of	T3	or	the	TRβ	agonist	GC1	was	detected	following	either	TG68	or	IS25,	
demonstrating the hepato-specificity of these novel TRβ agonists.
Conclusions: The	present	study	shows	that	TG68	and	IS25	induce	massive	hepato-
cyte	proliferation	without	overt	toxicity.	Hence,	these	agents	may	have	a	significant	
clinical application for regenerative therapies in liver transplantation or other surgical 
settings.
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1  | INTRODUC TION
The liver plays a fundamental role in the metabolic functions of the 
body and possesses a remarkable capacity to adapt to metabolic 
perturbations.	 Liver	 regeneration	 after	 partial	 hepatectomy	 (PH)	
typifies one such capacity in that the organ shifts instantly from a 
quiescent	state	to	a	rapidly	growing	one.1	The	unique	ability	of	the	
liver to rapidly restore its mass has long been a focus of research not 
only	for	scientific	purposes	but	also	for	clinical	applications.	Indeed,	
it has been shown to be lifesaving in cases of end-stage liver dis-
ease and in the transplantation of partial liver grafts.2	However,	the	
capacity	of	 liver	 to	 regain	 its	original	mass	and	function	 is	 limited,	
making	the	requirement	for	a	sufficient	liver	volume	a	factor	limiting	
the	application	of	liver	surgery.	Therefore,	search	for	agents	capable	
of inducing hepatocyte proliferation in the absence of liver injury 
and able to accelerate the replacement of cell loss has been actively 
pursued.3	Among	the	mitogenic	agents	so	far	 identified,	 ligands	of	




receptors	(TRs).3-5	Since	T3	is	a	naturally	occurring	mitogen,5-7 it has 
been the focus of great interest as a potential therapeutic agent. 
Unfortunately,	 its	use	may	cause	significant	side	effects,	 in	partic-
ular	 cardiac	dysfunction,	 that	 is	 tachycardia,	 arrhythmias	 and	pre-
cipitation	of	ischaemic	episodes	or	heart	failure	and	thyrotoxicosis.8 




a selective modulation of the β	isoform	(TRβ),	therefore	allowing	to	






that	 treatment	with	GC-1	 causes	 a	 reduction	 in	 triglyceride	 levels	
greater	 than	 that	produced	by	equimolar	doses	of	T3.14 These ef-
fects were achieved at doses devoid of relevant side effects on heart 




fatty acid β-oxidation	and	reduced	levels	of	 inflammatory	markers.16 
Similarly,	MB07344	and	its	prodrug	MB07811	showed	anti-steatotic	
activity in different animal models.17,18	Due	to	their	beneficial	effects,	
two	 of	 the	 aforementioned	 designed	 analogues,	GC-1	 and	KB2115,	
commercially	known	as	sobetirome	and	eprotirome,	respectively,	en-
tered	human	clinical	trials	for	dyslipidaemia,	displaying	encouraging	re-
sults in the absence of harmful effects typically associated with thyroid 
hormones	(THs)	high	levels	(for	reviews,	see	19,20).	Unfortunately,	no	
F I G U R E  1  Structures	of	T3	and	novel	thyroid	hormone	receptor	β agonists
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phase	II	trials	for	GC-1	were	planned	and	a	phase	III	trial	with	KB2115	
was	terminated	due	to	unexpected	side	effects	not	observed	in	pre-
clinical studies on animals.21	 In	 spite	 of	 this	 disappointing	 result,	 a	
12-week	study	with	MGL-3196,	formerly	known	as	Resmetirom,	has	
recently been shown to potently reduce hepatic fat content after 12 
and	36	weeks	of	treatment	in	patients	with	non-alcoholic	steatohepa-
titis	(NASH),	a	subtype	of	non-alcoholic	fatty	liver	disease	(NAFLD),	in	
the presence of only mild adverse effects.22
Overall,	 although	 caution	 about	 the	 use	 of	 these	 analogues	
should be maintained as they could be endowed with some dele-
terious	 effects,	 still	 the	 possibility	 of	 their	 therapeutic	 use	 in	 dif-
ferent	human	pathologies,	including	conditions	associated	with	the	
impaired	regenerative	capacity	of	the	liver	or	to	NASH,	the	second	
indicator	 for	 liver	 transplantation	 in	 the	 United	 States,	 has	 to	 be	
considered.
Novel	halogen-free	TRβ selective agonist IS25 and its prodrug 
TG68	 (Figure	 1)	 have	 been	 recently	 identified.23,24	 Notably,	 both	
compounds	initially	exposed	to	in	vitro	analysis	of	cytotoxicity	and	
ADME-Tox/off-target	liability	revealed	a	convincing	lack	of	toxicity,	
supporting their progression in the drug discovery process.
Therefore,	we	investigated	here	the	effect	of	a	sub-chronic	treat-
ment with these two novel TRβ agonists on rat liver cell proliferation. 
We found that these agents induced hepatocyte proliferation in the 
absence	 of	 any	 sign	 of	 liver	 cell	 damage/toxicity,	 suggesting	 that	
they could be clinically useful in conditions where a rapid liver cell 
proliferation	 is	 required	or	when	 the	 regenerative	capacity	of	 this	
organ is impaired.
2  | MATERIAL S AND METHODS
2.1 | Animals and treatments
Five-week-old	male	 F-344	 rats	 (N	 =	 40)	 purchased	 from	Charles	
River	(Milano,	Italy)	were	maintained	on	a	standard	laboratory	diet	
(Ditta	Mucedola,	Milano,	 Italy).	The	animals	were	given	 food	and	




Ministry	 of	 Health	 (authorization	 number:	 560/2019-PR).	 TG68	
and	 IS25	were	dissolved	 in	drinking	water	at	3	different	concen-
trations	(12.5,	25	and	50	µg/100g	b.w.).	The	highest	dose	of	both	
the compounds was selected on the basis of the mitogenic activity 
on rat and mouse liver showed by a similar dose of the analogue 
GC-1,25,26 whereas the oral administration was chosen as the ideal 
route of administration for future translational studies. Controls 
received	only	drinking	water.	A	 further	group	of	animals	was	 fed	
a	 T3-supplemented	 diet	 (4mg/kg	 of	 diet)	 (For	 the	 Experimental	
Protocol	 see	 Figure	 2A).	 For	 the	 measurement	 of	 hepatocyte	
proliferation,	 animals	 received	 bromodeoxyuridine	 (BrdU,	 1g/L)	
in drinking water during the one-week treatment period. In stud-
ies	 addressed	 to	 investigate	 pancreatic	 acinar	 cell	 proliferation,	





Immediately	 after	 sacrifice,	 sections	 of	 the	 liver	 were	 fixed	
in	 10%	buffered	 formalin	 and	 processed	 for	 staining	with	 haema-
toxylin-eosin	 or	 immunohistochemistry.	 The	 remaining	 liver	 was	
snap-frozen	in	liquid	nitrogen	and	kept	at	−80°C	until	use.
2.2 | Histology and Immunohistochemistry
Liver,	 pancreas,	 kidney	 and	 heart	 sections	 were	 fixed	 in	 10%	 of	
buffered	 formalin	 and	processed	 for	 staining	with	haematoxylin-
eosin	 (H&E)	 or	 immunohistochemistry	 (IHC).	 For	 BrdU	 detec-
tion,	 paraffin-embedded	 4	 µm	 sections	 were	 deparaffinized,	
treated	with	HCl	2N	 for	1h	 and	 then	with	0,1%	 trypsin	 at	 37°C.	
Sections	 were	 sequentially	 incubated	 with	 goat	 serum	 (Abcam),	
mouse	 monoclonal	 anti-BrdU	 antibody	 (Becton	 Dickinson,	 San	














following morphological criteria: cytoplasmic eosinophilia and frag-
mentation of nuclei. Only membrane-surrounded apoptotic bodies 
containing	nuclear	 fragments	were	 recorded.	The	Apoptotic	 index	
(AI)	was	calculated	as	number	of	apoptotic	bodies/field	at	X40	mag-
nification.	At	least	20	fields	per	rat	liver	were	scored.	Apoptosis	was	
also	determined	by	 IHC	analysis	of	 the	cleaved	 form	of	caspase-3	
(Cas-3)	as	described	by	Eckle	et	al,27 using rabbit monoclonal anti-
caspase-3	antibody	(Cell	Signaling,	Danvers,	MA).	AI	was	calculated	
as	number	of	Cas-3-positive	cells/field	at	X40	magnification.	At	least	
20 fields per rat liver were scored.
2.4 | RNA extraction and quantitative PCR analysis
Total	RNA	was	extracted	from	50	to	70	mg	of	frozen	 liver	 from	rats	
treated with 50 μg	 of	 TG68	 or	 IS25	 or	 vehicle	 or	 T3	 with	 TRIzol	











tification analysis for each gene was calculated by 2-ΔΔCt method.
2.5 | Western blot analysis
Total	 cell	 extracts	 were	 prepared	 from	 frozen	 livers.	 Liver	 tissue	
was	 homogenized	 with	 Bullet	 Blender	 Tissue	 Homogenizer	 (Next	
Advance,	Troy,	NY,	USA)	in	hot	LB	buffer	(1/2	H20,	¼	SDS	10%,	¼	
TRIS-HCl	 0.5M	 pH6.8)	 for	 2	minutes	 at	 maximum	 speed.	 Protein	
amount	was	quantified	with	BCA	(Pierce,	Thermo	Fisher,	Waltham,	
MA,	USA)	according	to	manufacturer's	instructions.	30	μg of whole 





Analysis of serum free triiodothyronine (FT3), free tiroxine 
(FT4), triglycerides (TGs), cholesterol (CH), glucose, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alka-
line phosphatase (ALP), gamma-glutamyl transferase (GGT) and 
total serum bilirubin (TSB): Immediately	 after	 sacrifice,	 blood	
samples	 were	 collected	 from	 the	 abdominal	 aorta,	 serum	 was	
separated	 by	 centrifugation	 (2000	 g	 for	 20	minutes)	 and	 tested	
for	 triglycerides,	 cholesterol,	 aspartate	 aminotransferase	 and	
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alanine aminotransferase using a commercially available kit from 
Boehringer	(Mannheim,	Germany).
2.6 | Statistical Analysis
All	 data	were	 expressed	 as	 the	mean	±	 SD	unless	 otherwise	 indi-
cated. Differences between groups were compared using one-way 
ANOVA.
3  | RESULTS
3.1 | Sub-chronic treatment with TG68 and IS25 
does not elicit T3-associated changes in liver, heart 
and kidney weight
Initial	 studies	 were	 performed	 to	 explore	 the	 effect	 of	 different	
doses	of	TG68	and	IS25	on	liver	cell	proliferation.	To	this	aim,	rats	
were	exposed	to	an	experimental	protocol	consisting	of	the	admin-










and,	 as	 a	 consequence,	 an	 enhanced	 heart/body	 weight	 ratio	
(Figure	2E).	Indeed,	necroscopy	on	T3-treated	rats	showed	a	marked	
hypertrophy of the left ventricle and the septum with increased 
muscle	stiffness	and	reduction	in	the	left	ventricular	cavity	size.	No	
such effect was found in the heart of animals treated at all doses of 
both	analogues,	showing	that	the	preferential	binding	to—and	acti-
vation	of—TRβ does not result in cardiac hypertrophy.
Another	 organ	 severely	 affected	 by	 T3	 is	 the	 kidney.28 
Accordingly,	the	kidney	weight	and	the	ratio	of	kidney/body	weight	
were greatly and significantly increased after the administration of 
thyroid	hormone	(Figure	2F).	No	such	effect	was	observed	following	
TG68	or	IS25.
F I G U R E  3  Serum	levels	of	free	T3	(fT3),	free	T4	(fT4),	glucose,	cholesterol	and	triglycerides	(TGs).	Rats	were	treated	according	to	
Figure	2A.	Results	were	expressed	as	means	±	SD	of	3-5	rats	per	group.	(one-way	ANOVA)





3.2 | TG68 and IS25 induce hepatocyte proliferation
Our	 previous	 findings	 showed	 that	 T3	 and	 two	other	 analogues—
Sobetirome	 and	 Eprotirome—exert	 a	 powerful	mitogenic	 effect	 in	
the	liver,	suggesting	their	possible	use	in	regenerative	medicine.29,30 
Therefore,	 we	 investigated	whether	 TG68	 and	 IS25	 could	 elicit	 a	
proliferative	response	in	this	organ	as	well.	As	shown	in	Figure	4A,B,	
one-week	treatment	with	either	TG68	and	IS25	at	all	doses	induced	
a	 strong	hepatocyte	proliferation,	 as	assessed	by	BrdU	 incorpora-
tion.	 Indeed,	 Labelling	 index	 (LI)	 displayed	 a	 3-	 to	 6-fold	 increase	










F I G U R E  4  Effect	of	sub-chronic	treatment	with	TG68	and	IS25	on	hepatocyte	proliferation.	A)	Microphotograph	illustrating	the	
presence	of	several	BrdU-positive	hepatocyte	nuclei	(X20,	counterstained	with	haematoxylin);	rats	were	sacrificed	1	week	after	continuous	
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The	mitogenic	effect	of	TG68	and	 IS25	was	 further	confirmed	
by	Western	blot	analyses	of	 cell	 cycle-related	proteins.	 Indeed,	as	
shown	in	Figure	4D,	the	protein	content	of	cyclin	D1,	cyclin	A	and	
PCNA	was	enhanced	 in	 the	 liver	of	 rats	 treated	with	 the	 two	TRβ 
agonists compared to that of control animals.
Histological	examination	showed	features	very	similar	to	those	
of	normal	liver	without	those	traits	typical	of	T3,	such	as	an	almost	
complete depletion of cytoplasmic components in the hepatocytes 
due to the catabolic effect of the thyroid hormone and resulting in 
increased	nuclear/cytoplasmic	ratio	(Figure	4A).	Notably,	while	cel-
lular	changes	similar	to	those	induced	by	T3	were	also	observed	after	
Eprotirome	treatment,30 no such changes were observed even at the 
highest dose of the two novel thyromimetics.
3.3 | Thyromimetic-induced hepatocyte 
proliferation is not associated with liver injury
To	 investigate	whether	 hepatocyte	 proliferation	 induced	by	TG68	
and	IS25	could	be	a	compensatory	response	to	liver	cell	necrosis,	we	
assessed the levels of serum transaminases. The results showed no 
significant	changes	of	ALT	and	only	a	very	slight	increase	of	AST	in	

















ALP	 levels	were	strongly	enhanced	by	T3	 (almost	4-fold	 increase),	
with	only	small	modifications	in	TG68-treated	animals.
Next,	we	 investigated	whether	 the	 two	 agonists	 could	 induce	
apoptosis.	Apoptotic	bodies	(ABs)	can	be	clearly	identified	as	mem-
brane-surrounded	globules	containing	nuclear	fragments	(Figure	5B,	
bottom	 right).	 Therefore,	 we	 scored	 their	 incidence	 on	 H&E	 liver	
sections	of	control	rats	and	of	animals	treated	with	TG68	and	IS25.	
As	shown	in	Figure	5B,	only	a	negligible	number	of	ABs	was	detected	
in control liver as well as in the liver of rats treated with the two 
thyromimetics.	 Accordingly,	 the	 Apoptotic	 index	 (AI)	 revealed	 no	
change	 in	 the	number	of	ABs	between	 treated	and	untreated	ani-
mals	(Figure	5C).




AI	 did	 not	 reveal	 any	 significant	 difference	 between	 control	 and	
treated	rats	(Figure	5E).
Since the dose of 50 μg	of	TG68	and	IS25	displayed	the	maximal	
mitogenic	potency	in	the	absence	of	liver	injury,	this	concentration	
was	selected	for	further	experiments.
3.4 | TG68 and IS25 induce the expression of TR 
target genes
It was previously shown that IS25 binds and specifically activates 
TRβ receptor in vitro.23,24 To assess whether in vivo hepatocyte 
proliferation induced by the novel TRβ agonists is preceded by TR 
activation,	 we	 evaluated	 the	 expression	 of	 two	well-established	
TRβ-target	genes,	deiodinase	1	(Dio1)	and	Spot14	(Spot14)	follow-
ing	treatment	with	a	single	 intragastric	 (i.g.)	dose	of	50	μg/100 g 
b.w.	of	either	TG68	or	 IS25.	An	equal	volume	of	 the	vehicle	and	
a	single	 i.g.	dose	of	T3	(20	μg/100	g	b.	w.)	were	given	as	a	nega-
tive	 and	 positive	 control,	 respectively	 (Figure	 6A).	 As	 shown	 in	
Figure	 6B,C	 qRT-PCR	 analysis	 revealed	 a	 statistically	 significant	
induction	 of	 these	 two	 genes	 6	 hours	 after	 either	 T3	 or	 IS25.	
Increased	expression	of	Dio1	and	Spot14	was	observed	also	after	
TG68	treatment,	although	it	did	not	reach	statistical	significance.
3.5 | TG68 and IS25 do not induce pancreatic acinar 
cell proliferation
It	 has	 been	 reported	 that	 T3	 and	 GC-1	 exert	 a	 strong	 mitogenic	




effect was evident in the pancreas of rats treated with the two 
novel thyromimetics. These results suggest that in addition to the 
selective affinity for TRβ,	IS25	and	TG68	can	also	be	considered	as	
hepato-specific.
3.6 | TG68 and IS25, unlike T3, do not induce 
renal or cardiac hypertrophy or proliferation
T3-induced	 renal	 and	 cardiac	 hypertrophy	 is	 associated	 with	
enhanced	proliferation	of	renal	and	cardiac	cells,	including	myo-
cardiocytes.33-35 To investigate whether the two agonists share 
the	mitogenic	effect	of	T3	 in	 these	 tissues,	we	determined	 the	
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proliferative	 activity	 by	 BrdU	 immunostaining.	 As	 shown	 in	
Figure	S2A,B,	while	T3	induced	a	strong	proliferation	both	in	the	




able difference was found in the two organs of rats treated with 
the two thyromimetics when compared to untreated animals 
(Figure	S3A,	B).
4  | DISCUSSION






suggesting that the mitogenic effect of these drugs may be due to 
binding and activation of TRβ.
Importantly,	the	liver	proliferative	response	induced	by	the	two	
TRβ	agonists	was	not	associated	with	liver	damage,	as	assessed	by	
biochemical determination of serum transaminases and by immu-
nostaining	for	caspase-3,	but	it	was	the	result	of	a	direct	effect	of	
these	 drugs	 enabling	 quiescent	 hepatocytes	 to	 re-entry	 into	 the	
cell cycle.
In	 the	 last	 few	 years,	 many	 thyromimetics	 have	 been	 de-
signed to be used to reduce hypercholesterolaemia and/or 
hypertriglyceridemia	 in	 the	absence	of	T3-induced	adverse	 thy-
rotoxic	 effects	 on	 the	 heart,	 skeletal	 muscle,	 bone	 or	 pituitary	
gland.13,19,20,32,36,37	After	initial	encouraging	results,	the	develop-
ment	of	some	of	these	drugs	(ie	KB2115,	GC-1)	was	hampered	due	
to unwanted side effects.21
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Another	 powerful	 effect	 exerted	 by	 synthetic	 TRβ agonists is 
their	mitogenic	ability.	Indeed,	similar	to	T3,	both	GC-1	and	KB2115	
induce rat hepatocyte proliferation.25,30
Our present data demonstrating a strong hepatomitogenic ef-
fect	 of	 IS25	 and	 TG68	 suggest	 that	 these	 compounds	 could	 be	
useful in regenerative medicine to manage conditions whereby a 
rapid	 liver	 regeneration	 is	 required,	 such	 as	 in	 the	 living-related	
transplantation,	or	in	the	elderly	status	that	is	characterized	by	an	
impaired liver regenerative capacity.38,39	Indeed,	previous	studies	
have	shown	that	T3	and	GC-1	improved	the	regenerative	response	
of	 rodent	 livers	 after	 70%	 or	 90%	 hepatectomy	 and	 stimulated	
liver	 cell	 proliferation	 in	 aged	 rats	when	 given	prior	 to—or	 after	
70%	PH.29,40-42
Of	note,	unlike	T3	or	GC-1,	 the	 two	novel	TRβ agonists inves-
tigated	were	mitogenic	only	for	the	liver	and	not	for	other	tissues,	






in the molecules is typically handled by the hepatocytes due to their 
highly	efficient	drug-metabolizing	system.	Since	aniline	derivatives	
undergo	hepatic	 biotransformation,	 it	 is	 possible	 that	most	 of	 the	
effects	 exerted	 by	 IS25	 and	 TG68	 are	 hepato-specific	 instead	 of	
systemic	as	observed	with	GC-1.	Future	 investigations	are	needed	
to gain a detailed understanding of the biotransformation pathways 
involving	IS25	and	TG68.
Irrespectively of the mechanisms responsible for such differ-
ences,	the	powerful	hepatocyte	mitogenic	capacity	 in	the	absence	
of	T3-associated	harmful	side	effects,	associated	with	the	absence	
of	 proliferative	 response	 in	 extrahepatic	 organs/tissues	 (pancreas,	
kidney,	heart),	 represent	an	 important	 improvement	 in	 the	field	of	
regenerative therapies.
Another	 relevant	 point	 raised	 by	 these	 results	 is	 the	 potential	
usefulness	of	these	analogues	to	reduce	fatty	liver	and	consequently	





ture studies is the use of these novel TRβ agonists as therapeutic an-
ti-cancer	drugs.	In	fact,	it	has	been	demonstrated	that	a)	a	short	term	
treatment	with	GC-1	of	rats	carrying	preneoplastic	nodules	induced	
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